No Data
Leerink Partners Maintains IDEAYA Biosciences(IDYA.US) With Hold Rating, Announces Target Price $27
IDEAYA Biosciences' Trial Expansion and Regulatory Uncertainties Lead to Hold Rating
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $40 to $62
IDEAYA Biosciences: Promising Outlook With Regulatory Alignment and Strategic Expansion in Clinical Trials
Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
